NASDAQ:BIB ProShares Ultra Nasdaq Biotechnology (BIB) Price, Holdings, & News $82.85 +0.31 (+0.38%) Closing price 05/5/2026 03:59 PM EasternExtended Trading$82.84 -0.01 (-0.01%) As of 05/5/2026 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestTrendsBuy This Stock About ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BIB alerts:Sign Up Key Stats Today's Range$81.43▼$83.8850-Day Range$73.81▼$89.4552-Week Range$39.47▼$90.90Volume7,074 shsAverage Volume11,507 shsMarket Capitalization$77.05 millionAssets Under Management$76.82 millionDividend Yield0.59%Net Expense Ratio0.95%Aggregate RatingModerate Buy ETF Overview ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in derivatives that have similar daily performance characteristics as the inverse of the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund. Read More ProShares Ultra Nasdaq Biotechnology ExpensesTypeBIBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.56%0.57%0.54%0.53%Other Expenses0.39%0.47%0.55%0.51%0.55%Total Expense1.14%0.74%0.76%0.73%0.73%Fee Waiver-0.19%-0.71%-0.64%-0.50%-0.61%Net Expense0.95%0.59%0.63%0.62%0.60% Receive BIB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares Ultra Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIB ETF News HeadlinesProShares Ultra Nasdaq Biotechnology declares quarterly distribution of $0.0071March 26, 2026 | msn.comBIB: A Tactical 2 X Leveraged Biotech ETFOctober 23, 2025 | seekingalpha.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)UltraShort Nasdaq Biotechnology declares quarterly distribution of $0.1542September 25, 2025 | msn.comBIB ProShares Ultra Nasdaq Biotechnology ETF - Seeking AlphaJuly 23, 2025 | seekingalpha.comProShares Ultra Nasdaq Biotechnology declares quarterly distribution of $0.3964December 24, 2024 | msn.comSee More Headlines BIB ETF - Frequently Asked Questions How have BIB shares performed this year? ProShares Ultra Nasdaq Biotechnology's stock was trading at $79.78 at the beginning of the year. Since then, BIB shares have increased by 3.8% and is now trading at $82.85. Who are ProShares Ultra Nasdaq Biotechnology's major shareholders? Top institutional shareholders of ProShares Ultra Nasdaq Biotechnology include Kaizen Financial Strategies (0.60%). How do I buy shares of ProShares Ultra Nasdaq Biotechnology? Shares of BIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProShares Ultra Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares Ultra Nasdaq Biotechnology investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Meta Platforms (META), Salesforce (CRM). Fund Details IssuerProShares Fund NameProShares Ultra Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:BIB Inception Date4/7/2010 Fund ManagerMichael Neches, Tarak Dave Webwww.proshares.com Phone+1-240-4976400Fund Focus Asset ClassEquity BenchmarkNasdaq Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings273 Fund Statistics Assets Under Management$76.82 million Average Daily Volume$10.92 thousand Discount/Premium-0.06% Leveraged2.00 Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors, LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume5 Put Options2 Call Options3 Short Interest9,200 shs Miscellaneous Outstanding Shares930,000Beta1.25 Creation Unit50,000 Creation Fee$250.00 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 BIB HoldingsNASDAQ BIO INDEX SWAP BNP PARIBASHolding Weight: 38.00%NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NAHolding Weight: 29.32%NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NAHolding Weight: 27.37%NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONALHolding Weight: 19.51%NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALEHolding Weight: 16.27%NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AGHolding Weight: 4.68%Amgen (NASDAQ:AMGN)Holding Weight: 4.64%Gilead Sciences (NASDAQ:GILD)Holding Weight: 4.64%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 4.58%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 3.92%Full Holdings DetailsBIB Sector ExposureBIB Industry Exposure This page (NASDAQ:BIB) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredHow to collect $1,170/month from silverThere is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...Investors Alley | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredA U.S. Resource Gap Is a National Issue - and OpportunityAmerica still does not domestically produce one mineral tied to batteries, energy storage, and national defens...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
